Home›Stock Screener›Piramal Pharma

Piramal Pharma Share Price Today | Stock Price & Piramal Pharma Share Screener

PPLPHARMA Pharmaceuticals & Biotechnology
Live Share Price NSE
₹238.95
▼ -1.75 (-0.73%)
2026-11-18 00:00:00
Live Share Price BSE
₹238.95
▼ -1.35 (-0.56%)
2026-11-18 00:00:00

As of November 18, 2026, the live Piramal Pharma share price (NSE: PPLPHARMA) is ₹238.95 on NSE and ₹238.95 on BSE, down 0.73% from the previous close, with shares trading between ₹237.32 and ₹243.76 in today's trading session, and a 52-week range of ₹133.27–₹246.37. Track PPLPHARMA company valuation to gauge the company's total market size. Use the Piramal Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Piramal Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹2,671 and net income of ₹5, with EBITDA of ₹402, an operating margin of 13.0% and a profit margin of 0.2%.

Piramal Pharma Market Cap ₹32,045.55 Cr.
PPLPHARMA P/E Ratio (TTM) -156.10
Piramal Pharma P/B Ratio 4.00
EPS (TTM) ₹0.04
Dividend Yield 0.06%
Debt to Equity 0.65
PPLPHARMA 52 Week High ₹246.37
Piramal Pharma 52 Week Low ₹133.27
Operating Margin 13.00%
Profit Margin 0.19%
PPLPHARMA Revenue (TTM) ₹2,671.00
EBITDA ₹402.00
Net Income ₹5.00
Total Assets ₹17,965.00
Total Equity ₹8,163.00

Piramal Pharma Share Price Chart

Track the current stock price of Piramal Pharma with an interactive chart. Analyse PPLPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Piramal Pharma stock quote in one place.

The quote of ₹238.95 sits between the 52-week low of ₹133.27 and the 52-week high of ₹246.37, and the latest session moved -0.73% from the previous close.

Piramal Pharma Company Profile - Fundamental Screener

Screen Piramal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PPLPHARMA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Nandini Piramal listed as chairperson or CEO, and it trades under ISIN INE0DK501011.

Business Overview

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Nandini Piramal
ISIN INE0DK501011

Piramal Pharma Balance Sheet Screener

Screen PPLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹17,965, up from ₹15,678 in 2025.

Latest statistics put total assets at ₹17,965 and shareholder funds at ₹8,163, with a leverage ratio of 0.65.

Item 2026 2025 2024 2023 2022 2021

Assets

Total Assets 17,965 15,678 15,312 14,523 12,797 10,900
Current Assets 0 0 0 0 0 0
Fixed Assets 8,684 8,133 7,990 7,469 6,879 6,106

Liabilities

Total Liabilities 0 0 0 0 0 0
Current Liabilities 5,044 3,786 3,031 3,906 3,067 2,805
Non-Current Liabilities 0 0 0 0 0 0

Shareholders' Equity

Total Equity 8,163 8,126 7,911 6,774 6,697 5,605
Share Capital 1,327 1,324 1,323 1,193 1,186 995
Reserves & Surplus 6,836 6,801 6,588 5,580 5,511 4,610

Piramal Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Piramal Pharma income statement and profit fundamentals. Analyze PPLPHARMA quarterly results. Piramal Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹2,671 and net profit was ₹5, equal to earnings per unit of ₹0.04, at an operating margin of 13%.

In that period expenses were ₹2,268, interest cost ₹88 and tax ₹77. The next period listed, 2026-Jun, shows revenue of ₹2,379 and net profit of ₹-69.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 2,671 2,379 2,811 2,193 2,124 2,031 2,812 2,233 2,320 1,993 2,591 2,034 1,980 1,802 2,196
Expenses 2,268 2,075 2,467 1,985 1,885 1,827 2,193 1,867 1,900 1,747 2,053 1,723 1,646 1,617 1,812

Operating Costs and Margins

EBITDA 402 304 344 208 239 204 619 367 420 246 538 312 334 185 384
Operating Profit % 13.00% 9.00% 10.00% 7.00% 8.00% 6.00% 20.00% 15.00% 15.00% 10.00% 20.00% 12.00% 14.00% 8.00% 16.00%
Depreciation 233 224 218 213 203 197 243 197 192 185 196 186 185 174 184
Interest 88 88 83 89 82 86 104 103 108 107 114 106 110 119 104

Profit and Earnings

Profit Before Tax 82 -8 43 -94 -46 -79 273 67 120 -45 228 19 40 -107 95
Tax 77 62 52 42 53 3 119 63 98 44 126 9 35 -9 45
Net Profit 5 -69 -9 -136 -99 -82 154 4 23 -89 101 10 5 -99 50
EPS 0.04 -0.52 -0.07 -1.03 -0.75 -0.62 1.16 0.03 0.17 -0.67 0.77 0.08 0.04 -0.83 0.42

Piramal Pharma Cash Flow Screener - Liquidity Fundamentals

Screen PPLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹1,653, and net cash flow was an inflow of ₹794.

Over the same period, investing activities used ₹820 and financing activities used ₹39.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March

Cash from Operations and Investing

Operating Activities 1,653 892 1,005 484 766 598
Investing Activities -820 -488 -416 -1,334 -1,737 -4,464

Financing and Net Cash

Financing Activities -39 -441 -422 818 794 3,977
Net Cash Flow 794 -37 166 -32 -177 110

Piramal Pharma Shareholding Pattern Screener

See Piramal Pharma shareholding pattern with promoter, FII, and DII holdings. Check Piramal Pharma promoter holding and ownership changes for PPLPHARMA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 34.86%, foreign institutions 30.18%, domestic institutions 15.61% and the public 13.74%, spread across 450,661 shareholders.

The shareholder count was 450,661 in 2026-Mar, compared with 461,096 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 34.86% 34.80% 34.80% 34.95% 34.86% 34.86% 34.86% 35.02%

Institutional Investors

FII Holding 30.18% 12.52% 13.65% 31.49% 30.86% 30.27% 29.66% 30.59%
DII Holding 15.61% 14.57% 14.44% 14.78% 14.26% 14.89% 15.69% 12.12%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 13.74% 14.54% 13.27% 13.11% 14.07% 14.12% 14.11% 15.13%
Other Holding 5.61% 23.57% 23.84% 5.66% 5.95% 5.86% 5.69% 7.14%
Shareholder Count 450,661 461,096 413,197 432,843 458,430 462,511 453,830 297,996

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Piramal Pharma. Piramal Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.11 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.11 0.05%
2023-March ₹0.00 0.00%
2022-March ₹0.56 0.84%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Piramal Pharma Stock Index Membership - Nifty & Sensex

See which indices include Piramal Pharma stock. Check PPLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 21 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX BSEIPO.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEIPO
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
BSE INDEX SMLSEL
NIFTY 500
NIFTY ALPHA 50
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP

Piramal Pharma Market Events Screener - Corporate Actions

Get Piramal Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Piramal Pharma stock events that may affect PPLPHARMA share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 27, 2026, with a record date of October 27, 2026.

It is followed by Annual General Meeting dated July 30, 2026 and Quarterly Result Announcement dated July 29, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-27 2026-10-27 Quarterly Result Announcement NA 0.38%
2026-07-30 2026-07-30 Annual General Meeting NA 16.34%
2026-07-29 2026-07-29 Quarterly Result Announcement NA 7.79%
2026-04-28 2026-04-28 Quarterly Result Announcement NA 14.47%
2026-01-28 2026-01-28 Quarterly Result Announcement NA -9.31%
2025-11-05 2025-11-05 Quarterly Result Announcement NA -1.56%
2025-07-30 2025-07-30 Annual General Meeting NA 2.83%
2025-07-28 2025-07-28 Quarterly Result Announcement NA -6.75%
2025-07-16 2025-07-16 Dividend ₹ 0.14 /share 0.61%
2025-05-14 2025-05-14 Quarterly Result Announcement NA -0.02%
2025-01-28 2025-01-28 Quarterly Result Announcement NA 1.24%
2024-10-23 2024-10-23 Quarterly Result Announcement NA -2.78%
2024-07-26 2024-07-26 Annual General Meeting NA 5.86%
2024-07-12 2024-07-12 Dividend ₹ 0.11 /share 2.40%
2023-08-02 2023-08-02 Rights 5:46 1.87%

Piramal Pharma Competitors Screener - Peer Stocks Comparison

Screen PPLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Piramal Pharma Company Announcements - News & Reports Screener

Screen PPLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 31, 2026.

The next most recent announcements are dated October 30, 2026 and October 30, 2026.

Date Update Actions
2026-10-31 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-30 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-30 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-10-28 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-27 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-27 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-27 Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended September 30 2026 -
2026-10-27 Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 27Th October 2026 -
2026-10-16 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-16 Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September 2026 -
2026-10-01 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private Limited -
2026-10-01 Clarification On News Item Which Appeared In The Www.Thehindubusinessline.Com Dated September 30 2026 Captioned Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal PharmaS Aurora Facility. -
2026-09-30 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-30 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-30 Clarification sought from Piramal Pharma Ltd -
2026-09-29 Closure of Trading Window -
2026-09-29 Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-09-18 Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating -Niche Ninety Nine Capability And Certifications (OPC) Private Limited -
2026-09-14 Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA Inspection -
2026-09-08 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹238.95, within a 52-week range of ₹133.27 to ₹246.37. The P/E ratio is -156.10 and the P/B ratio is 4.00, with earnings per unit of ₹0.04. Market capitalisation stands at ₹32,045.55 Cr and the dividend yield is 0.06%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 6 balance sheet periods, 15 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.